Clinical Trial Detail

NCT ID NCT02860780
Title A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

non-small cell lung carcinoma

colon cancer

Advanced Solid Tumor

Therapies

Prexasertib + Ralimetinib

Age Groups: adult senior

Additional content available in CKB BOOST